Danazol in treatment of angio-immunoblastic lymphadenopathy.
The clinical manifestations of angio-immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of infections, the therapeutic management of AILD is difficult. The achievement of complete remission (CR) by the patient described here using a danazol-based regimen raises the hope that treatment of this disease with a noncytotoxic drug may be possible. The rationale behind and advantages of using danazol are discussed.
Banavali
S D
SD
Department of Medical Oncology, Tata Memorial Hospital, Bombay, India.
Parikh
P M
PM
Charak
B S
BS
Modi
A
A
Iyer
R
R
Nadkarni
K S
KS
Saikia
T
T
Gopal
R
R
Soman
C S
CS
Advani
S H
SH
D003613:Danazol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy*; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D012074:Remission Induction
D011245:Pregnadienes; D003613:Danazol